文献速递颈动脉与弓上血管

经颈动脉血运重建监测项目七年结果:与经股动脉支架置入及颈动脉内膜剥脱术的比较

Seven years of the transcarotid artery revascularization surveillance project, comparison to transfemoral stenting and endarterectomy.
PubMed 文献 · J Vasc Surg · 2024-05-29

基于VQI 2016年9月至2023年8月数据,采用逆概率加权比较TCAR、tfCAS与CEA的院内结局。tfCAS的卒中/死亡风险高于TCAR(2.9% vs 1.6%;aOR 1.84)和CEA(2.9% vs 1.3%;aOR 2.21);CEA略低于TCAR(1.3% vs 1.6%;aOR 0.83)。

要点

  • tfCAS的卒中/死亡风险高于TCAR(2.9% vs 1.6%;aOR 1.84)和CEA(2.9% vs 1.3%;aOR 2.21)。
  • CEA的卒中/死亡风险略低于TCAR(1.3% vs 1.6%;aOR 0.83)。
  • CEA的心肌梗死和颅神经损伤风险高于TCAR(心肌梗死0.6% vs 0.5%,aOR 1.31;颅神经损伤2.3% vs 0.3%,aOR 9.42)。

核心结论

  • tfCAS可能对特定患者有益,但CEA和TCAR相关的较低卒中/死亡风险更受青睐。
  • 在CEA与TCAR之间选择时,需权衡心肌梗死和颅神经损伤等额外手术因素和结局,尤其在卒中/死亡风险相似时。
  • 评估可能从某种手术中获益的亚组对知情决策和改善颈动脉狭窄患者治疗至关重要。

研究设计与样本

  • 利用VQI 2016年9月至2023年8月数据,采用逆概率治疗加权进行风险校正分析,比较TCAR vs tfCAS、CEA vs tfCAS、TCAR vs CEA的院内结局。
  • 共纳入TCAR 50,068例、tfCAS 25,361例、CEA 122,737例。
  • 主要结局为院内卒中/死亡,次要结局包括心肌梗死和颅神经损伤。

主要发现

  • tfCAS的卒中/死亡风险高于TCAR(2.9% vs 1.6%;aOR 1.84;95%CI 1.65-2.06;P<.001)。
  • tfCAS的卒中/死亡风险高于CEA(2.9% vs 1.3%;aOR 2.21;95%CI 2.01-2.43;P<.001)。
  • CEA的卒中/死亡风险略低于TCAR(1.3% vs 1.6%;aOR 0.83;95%CI 0.76-0.91;P<.001)。
  • tfCAS的颅神经损伤风险低于TCAR(0.0% vs 0.3%;aOR 0.00;95%CI 0.00-0.00;P<.001)和CEA(0.0% vs 2.3%;aOR 0.00;95%CI 0.0-0.0;P<.001)。
  • tfCAS的心肌梗死风险低于CEA(0.4% vs 0.6%;aOR 0.67;95%CI 0.54-0.84;P<.001)。

临床怎么用

  • 作者认为,尽管tfCAS可能对特定患者有益,但CEA和TCAR相关的较低卒中/死亡风险更受青睐。
  • 作者指出,在CEA与TCAR之间选择时,需权衡心肌梗死和颅神经损伤等额外手术因素和结局。
  • 作者认为,评估可能从某种手术中获益的亚组对知情决策和改善患者治疗至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study utilizes the latest data from the Vascular Quality Initiative (VQI), which now encompasses over 50,000 transcarotid artery revascularization (TCAR) procedures, to offer a sizeable dataset for comparing the effectiveness and safety of TCAR, transfemoral carotid artery stenting (tfCAS), and carotid endarterectomy (CEA). Given this substantial dataset, we are now able to compare outcomes overall and stratified by symptom status across revascularization techniques. METHODS: Utilizing VQI data from September 2016 to August 2023, we conducted a risk-adjusted analysis by applying inverse probability of treatment weighting to compare in-hospital outcomes between TCAR vs tfCAS, CEA vs tfCAS, and TCAR vs CEA. Our primary outcome measure was in-hospital stroke/death. Secondary outcomes included myocardial infarction and cranial nerve injury. RESULTS: A total of 50,068 patients underwent TCAR, 25,361 patients underwent tfCAS, and 122,737 patients underwent CEA. TCAR patients were older, more likely to have coronary artery disease, chronic kidney disease, and undergo coronary artery bypass grafting/percutaneous coronary intervention as well as prior contralateral CEA/CAS compared with both CEA and tfCAS. TfCAS had higher odds of stroke/death when compared with TCAR (2.9% vs 1.6%; adjusted odds ratio [aOR], 1.84; 95% confidence interval [CI], 1.65-2.06; P < .001) and CEA (2.9% vs 1.3%; aOR, 2.21; 95% CI, 2.01-2.43; P < .001). CEA had slightly lower odds of stroke/death compared with TCAR (1.3% vs 1.6%; aOR, 0.83; 95% CI, 0.76-0.91; P < .001). TfCAS had lower odds of cranial nerve injury compared with TCAR (0.0% vs 0.3%; aOR, 0.00; 95% CI, 0.00-0.00; P < .001) and CEA (0.0% vs 2.3%; aOR, 0.00; 95% CI, 0.0-0.0; P < .001) as well as lower odds of myocardial infarction compared with CEA (0.4% vs 0.6%; aOR, 0.67; 95% CI, 0.54-0.84; P < .001). CEA compared with TCAR had higher odds of myocardial infarction (0.6% vs 0.5%; aOR, 1.31; 95% CI, 1.13-1.54; P < .001) and cranial nerve injury (2.3% vs 0.3%; aOR, 9.42; 95% CI, 7.78-11.4; P < .001). CONCLUSIONS: Although tfCAS may be beneficial for select patients, the lower stroke/death rates associated with CEA and TCAR are preferred. When deciding between CEA and TCAR, it is important to weigh additional procedural factors and outcomes such as myocardial infarction and cranial nerve injury, particularly when stroke/death rates are similar. Additionally, evaluating subgroups that may benefit from one procedure over another is essential for informed decision-making and enhanced patient care in the treatment of carotid stenosis.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Straus S, Yadavalli SD, Allievi S, et al. Seven years of the transcarotid artery revascularization surveillance project, comparison to transfemoral stenting and endarterectomy. J Vasc Surg. 2024. PMID: 38821431. doi:10.1016/j.jvs.2024.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。